Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates sanofi researchsquare COVID19 SARSCoV2 BoosterVaccine Primates Neutralization Booster
By Dr. Liji Thomas, MDDec 23 2022Reviewed by Aimee Molineux Early in 2021, vaccines were rolled out against the severe acute respiratory syndrome coronavirus 2 , decreasing the number of infections, hospitalizations, and mortality rate.
Ideally, several booster doses would be given each year to keep up with the change in currently circulating variants, typically at a gap of 3-4 months, since November 2021, when the Omicron BA.1 variant was first detected. New booster vaccines can unlikely be developed fast enough to keep up with this pace.
What did the study show? Earlier, the scientists demonstrated a D14 spike candidate that was both safe and immunogenic. Following the emergence of the Beta variant in South Africa, they now used this spike variant in the candidate booster candidate. They conducted a non-human primate study since earlier studies showed robust cross-reactivity against the VOCs identified so far and even severe acute respiratory syndrome coronavirus 1 when they had previously been primed with the D14 vaccine.
The NHPs showed a protective response detected at six months, against Omicron BA.1 and SARS-CoV-1, in all animals. Animals that had shown a low spike-specific memory B cell response after the primary protocol showed an increase in this aspect of immunity three months after the booster dose. While bivalent vaccines containing both the ancestral spike and the latest Omicron spike at the time of vaccine development have been recommended in some countries, it appears from available data, albeit scarce, that this is not associated with an adequate rise in protective efficacy compared to the parental vaccines, against all SARS-CoV-2 variants. Moreover, protection against infection by Sarbecoviruses not closely related to the current virus decreased.
Conversely, with subunit vaccine priming doses, the Beta spike-based booster was associated with a small fall in anti-D614G nAb titers at 100 days, by about four-fold, but not in the other formulations. Independent of the initial priming vaccine platform, the Beta-containing vaccine booster might offer durable and high cross-neutralizing antibody responses to all VOCs and to SARS-CoV-1 for six or more months.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
China’s Fast And Deadly Road To Covid Recovery | OilPrice.comChina has officially pivoted from its zero-Covid policy, meaning it is now just a question of time before it ‘exits’ Covid and its oil demand rebounds
Lire la suite »
China’s Covid Deaths Could Be Above 5,000 Per Day | OilPrice.comAccording to health data firm Airfinity, more than 5,000 people are probably dying each day from COVID-19 in China, with the firm’s mortality risk analysis suggesting that 1.3 to 2.1 million people could die in the country’s current COVID outbreak.
Lire la suite »
Most common Covid symptoms as cases rise & you might confuse them for a coldAS Christmas approaches, no one wants to be struck down with illness. With many people currently battling with a cough or a sniffle, it can be easy to dismiss your symptoms as a cold. That’s …
Lire la suite »
Covid, cold, flu, Strep A and RSV symptoms - how to tell winter lurgies apartWinter is prime time for many different illnesses to spread around, so here are all the differences between symptoms.
Lire la suite »
Latest Covid symptoms as cases surge 25% before ChristmasLatest Covid symptoms as cases surge 25% ahead of Christmas
Lire la suite »